SpyBiotech

About SpyBiotech

SpyBiotech is a clinical stage company focused on developing vaccines against infectious diseases and cancer using its proprietary protein superglue technology, SpyTag/SpyCatcher. The company aims to address major human health challenges by creating safe and effective vaccines with greater ease and speed.

Products & Services

Vaccines for Infectious Diseases and Cancer:Utilizing proprietary protein superglue technology to develop safe and highly effective vaccines.

SPYVLP01:A vaccine candidate targeting Human Cytomegalovirus (HCMV), currently in Phase I clinical trial.

Specialties

Protein Superglue Technology (SpyTag/SpyCatcher) Vaccine Development Infectious Disease Prevention Cancer Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 4094561 MR: - FA: $4,094,561 FAN: 4094561	D: 2023-03-20 FD: 2023-03-20	1 investors

Grant Latest

2023-03-20

$4.1M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sumi Biswas

President, Co-founder, Chief Scientific Officer

LinkedIn (Pro only)

P

Prakash Bhuyan

Chief Medical Officer

LinkedIn (Pro only)

K

Keith Dewedoff

Chief Financial Officer

L

Laura Bilbé

Laboratory Manager

D

David Bitto

Senior Scientist II

L

Lesley Bowman

Principal Scientist I

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

SpyBiotech Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised